<DOC>
	<DOCNO>NCT01626573</DOCNO>
	<brief_summary>This study evaluate 28-day course follow 56-day course INCB039110 patient active rheumatoid arthritis ( RA ) . The study evaluate safety efficacy parameter INCB039110 .</brief_summary>
	<brief_title>A Study Exploring Safety , Tolerability , Efficacy 28 Day Course Followed Additional 56 Day Course INCB039110 Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects active RA age 18 75 year age meet tender swell joint assessment expectation define study protocol . cReactive protein ( CRP ) erythrocyte sedimentation rate ( ESR ) laboratory value meet minimal study protocol expectation . Females pregnant breastfeeding . Men woman comply requirement avoid father child become pregnant , respectively . Subjects treat biologic agent within 12 week prior first dose study drug . ( 12 month case rituximab . ) Subjects history currently suspect inflammatory disease RA . Subjects history hematological disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>Active</keyword>
</DOC>